See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
See the latest data presented at TVT 2023 showing sustained haemodynamic performance to 1 year and highlighting our latest patient cohort showing best results to date at 30 days.
Watch this physician panel and hear Drs Christopher Meduri, Susheel Kodali, and João Cavalcante discuss early safety and feasibility of the first-in-class biomimetic transcatheter aortic valve – DurAVR™ THV.
LIVE PHYSICIAN INTERVIEW AT AGM
CEO Wayne Paterson and Dr. Karl Poon discuss his experience with DurAVR™ at Anteris Technologies’ Annual General Meeting.
POWERED BY SCIENCE. DEVELOPED BY EXPERTS.
Shaped for native haemodynamic performance for patients with severe aortic stenosis, DurAVR™ Transcatheter Heart Valve elevates science.
Anteris Technologies is a Structural Heart Company committed to discovering, developing, and delivering a pipeline of innovative medical device solutions that aim to improve the health outcomes of patient populations and dramatically improve people's lives.
INVEST IN ANTERIS (ASX: AVR)
We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.
We drive awareness and adoption of our ADAPT® technology through our key partnerships while attracting the best talent, fostering a culture of agility, creativity, quality, and excellence. We apply scientific curiosity and innovative thinking to deliver transformative solutions to patients.